Although oncogenic functions and the clinical significance of Wilms tumor 1 (WT1) have been extensively studied in acute leukemia, the regulatory mechanism of its transcription still remains to be determined. We found a significant correlation among the amounts of WT1, GATA-1 and GATA-2 mRNAs from leukemia and solid tumor cell lines. Overexpression and small interfering RNA (siRNA) transfection experiments of GATA-1 and GATA-2 showed that these GATA transcription factors could induce WT1 expression. Promoter analysis showed that the 5 0 promoter did not explain the different WT1 mRNA levels between cell lines. The 3 0 enhancer, especially the distal sites out of six putative GATA binding sites located within the region, but not the intron 3 enhancer, were essential for the WT1 mRNA level. Electrophoretic mobility shift assay (EMSA) showed both GATA-1 and GATA-2 bound to these GATA sites. Besides acute leukemia cell lines, solid tumor cell lines including, TYK-nu-cPr also showed a high level of WT1 mRNA. We showed that GATA-2 expression is a determinant of WT1 mRNA expression in both TYK-nu-cPr cells and HL60 cells without GATA-1 expression. Taken together, these results suggest that GATA-1 and/or GATA-2 binding to a GATA site of the 3 0 enhancer of WT1 played an important role in WT1 gene expression.
Introduction
Wilms tumor 1 (WT1) gene was isolated as a tumor suppressor gene responsible for Wilm's tumor, a kidney neoplasm of childhood. The gene product, WT1, represses the transcription of growth factors, growth factor receptors and other genes. [1] [2] [3] On the other hand, WT1 has been regarded as an oncogene for leukemia and some solid tumors because high expression levels of WT1 mRNA were observed in these diseases, and in vivo and in vitro studies showed the positive roles it plays in cell growth and transformation. [4] [5] [6] [7] [8] WT1 mRNA is reportedly a good clinical marker for disease progression, diagnosis and detection of the minimal residual diseases of myelodysplastic syndromes and leukemia. [9] [10] [11] Thus, depending on the cells and situations expressing WT1, it displays both anti-oncogenic and oncogenic characters. 12 Despite the fact that the oncogenic functions of WT1 have been well documented, its gene-expression mechanism remains undetermined.
In the promoter analysis of WT1 gene, Cohen et al. 13 reported the importance of Sp1 for mRNA expression, although the promoter region may not determine the tissue-specific manner of WT1 expression. 13, 14 Regarding this point, the 3 0 enhancer located 450 kb downstream of the promoter was identified as increasing the basal transcription rate of the WT1 promoter in the erythroleukemia cell line K562.
14 Subsequently, Wu et al. 15 showed that GATA-1 may bind to this enhancer, which is reported to be specific in hematopoietic cells. 16 To date, in addition to Sp1 and GATA-1, PAX2 and PAX8 are also reported to be the transcription factors that regulate WT1 gene expression. [17] [18] [19] [20] Dehbi et al. 17 reported the binding sites of PAX2 and PAX8 in the 5 0 promoter of WT1 gene. Zhang et al. 20 indicated the importance of the intron 3 enhancer of WT1 gene, which was activated by GATA-1 and Myb.
These earlier results suggest that between the cells analyzed, the regulation of WT1 gene expression might be complex and heterogeneous. Furthermore, it was not clear what the major determinant of WT1 mRNA level is either in leukemia or in solid tumors. Although the GATA family has been shown to play critical roles in erythroid and other hematopoietic lineages, 21, 22 GATA-1 expression is low in M3, M4 and M5 of acute myelogeneous leukemia, 23 in which WT1 expression has been observed. Therefore, GATA-1 might not be sufficient to maintain full WT1 gene expression. For another transcription factor candidate, we focused on GATA-2, which is presented in cells at the earlydifferentiated stage of hematopoietic lineages. We examined the relationship between WT1, GATA-1 and GATA-2 mRNA from 20 leukemia cell lines and 26 acute leukemia bone marrows, as well as purified stem cell and progenitor cell fractions from two normal bone marrows. We also examined solid tumor cell lines with high WT1 expressions. There are no reports describing the regulatory mechanism of WT1 gene expression in these cell lines.
On the basis of our results, we discussed the functional relationship between Sp1 and WT1 expression and that between GATA and WT1 expression in leukemia cell lines and several solid tumor cell lines.
Materials and methods

Clinical samples and cell lines
After obtaining informed consent, bone marrow cells were collected from 23 acute myeloid leukemia (AML) patients and three ALL patients without Ph 1 chromosome. Normal control samples were derived from malignant lymphoma patients without bone marrow involvement as described earlier. 24, 25 Our analysis of WT1, GATA-1 and GATA-2 was approved by IRB (approved number 99) of the Nagoya University School of Medicine. Some leukemia cell lines were provided by Dr Hirokazu Nagai (National Hospital Organization, Nagoya Medical Center, Nagoya, Japan). Solid tumor cell lines with high WT1 mRNA levels 8 were the generous gifts of Dr Haruo Sugiyama (Osaka University Graduate School of Medicine, Osaka, Japan).
Quantitative reverse transcriptase-PCR
Quantitative reverse transcriptase-PCR was performed as described. 24, 25 WT1 mRNA was measured using the Light Cycler system (Roche Diagnostics, Mannheim, Germany). Each primer set and PCR conditions have been described before. 24, 25 GATA-1, GATA-2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNAs were measured with a Power SYBR Green master mix using the ABI PRISM 7000 sequence detection systems (Applied Biosystems Japan Ltd, Tokyo, Japan). After producing first-strand cDNA, quantitative PCR was carried out using the following primer sets:
0 ; reverse 5 0 -CCCCCTGCAAATGAGCCC-3 0 . PCR conditions were GATA-1, 95 1C for 10 s followed by 56 1C for 15 s; GATA-2, 95 1C for 10 s followed by 56 1C for 15 s; and GAPDH, 95 1C for 10 s followed by 63 1C for 15 s. Forty cycles were used for WT1, GATA-1, GATA-2 and GAPDH. GAPDH was used as the internal control for both clinical samples and cell lines. Relative mRNA was calculated as the respective mRNA/GAPDH mRNA in the log scale.
Western blotting
Western blotting of WT1, GATA-1, GATA-2 and Sp1 was carried out using the anti-WT1 antibody (clone 6F-H2, Dakocytomation, CA, USA), anti-GATA-1 (sc-265), anti-GATA-2 (sc-9008) and anti-Sp1 (sc-59) antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), respectively. We used the ECL chemiluminescence kit (Amersham Pharmacia Biotech, Buckinghamshire, UK) for signal detection.
Rapid amplification of 5
0 cDNA ends (5 0 RACE)
The transcription initiation point of WT1 was determined as described in the Supplementary information.
Cloning of WT1 promoter and enhancer regions
We obtained an B1.8-kb fragment covering the 5 0 region of exon1 of WT1 using the 5 0 rapid amplification of cloned ends. This fragment was inserted into the Kpn-I and Bgl-II sites of pGL3 basic vector (Promega, Madison, WI, USA), and used for the promoter analysis (À1807/Luc). Truncation and mutation of WT1 promoter were prepared by the PCR-based method. Similarly, the intron 3 and 3 0 enhancers of the WT1 were also obtained by the PCR-based method. Production of the truncation and mutation of 5 0 promoter and enhancer is described in the Supplementary information. 
Promoter and enhancer analysis
DNA transfection
Transfection of the expression vector was carried out using Trans IT-Jurkat, for Jurkat, and the calcium precipitation method for TYK-nu-cPr cells. GATA-1 and GATA-2 expression vectors were obtained from Dr Ritsuko Shimizu (Tsukuba University, Tochigi, Japan) and Dr Haruhiko Asano (Chubu University, Kasugai, Aichi, Japan), respectively. GATA-1 cDNA or GATA-2 cDNA was transferred into pcDNA3.1 vector (Invitrogen).
RNA interference
K562 cells (5 Â 10 5 ) were transfected with small interfering RNA (siRNA) (final 100 nM) using Oligofectamine reagent (Invitrogen). GATA-1 siRNA (ID no. 3197) and GATA-2 siRNA (ID no. 145419) were purchased from Ambion (Austin, TX, USA). Scrambled siRNA was purchased from Dharmacon (GE Healthcare Sciences, Tokyo, Japan).
Electrophoresis mobility shift assay
Nuclear extract was prepared from K562, Jurkat, Daudi, HL-60, TYK-nu-cPr, Sw480, Az521 and HepG2 cells. Electrophoretic mobility shift assay (EMSA) was performed as described earlier. 26 For the supershift experiment, anti-GATA-1 or anti-GATA-2 antibody (Santa Cruz Inc.) was added to the nuclear extract for 30 min at room temperature before mixing with biotin-labeled probes as described below. Forward, 5
0 -CATTTA TATCAGCCGTTTTTATCTTTTCCTG-3 0 ; reverse, 5 0 -CAGGAAA AGATAAAAACGGCTGATATAAATG-3 0 (Bold letters are the GATA binding motifs). In some experiments, mutated oligo was used. Proximal-mutated GATA: forward, 5
0 (Bold letters are the mutated GATA binding sites). Biotin label was attached to the 3 0 end of each forward probe (Sigma Genosys, Hokkaido, Japan).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay was carried out as described earlier. 26 K562, Jurkat and TYK-nu-cPr cells were used for the crosslinking with formaldehyde. For the immunoprecipitation, normal mouse IgG, anti-GATA-1-antibody (Santa Cruz, final concentration; 3 mg/ml) or anti-GATA-2-antibody (Santa Cruz) was added and incubated at 4 1C overnight. Immunocomplexes were extracted and crosslinking was reversed by heating the elutes at 65 1C overnight. The eluates were then digested with proteinase K at 50 1C for 5 h and extracted with phenol/chloroform/isoamyl alcohol. DNA was purified by ethanol precipitation. The WT1 enhancer region was amplified by PCR using primers 5 0 -GGGAATTCGACTCATTTATATCAG CCGTTTT-3 0 (forward) and 5 0 -GGGTCGACCCTGGCTCTTTCC GACTC-3 0 (reverse).
Results and discussion
Correlation between mRNA levels of WT1 and GATA-1/GATA-2 in acute leukemia clinical samples and cell lines
In Figure 1 , we analyzed 20 established leukemia cell lines to determine the correlation between WT1 and GATA-1/GATA-2 (Figures 1a and c) . Seventy-five percent of the cell lines showed high mRNA expression (more than 10 À3 of GAPDH mRNA), whereas others (such as Daudi and U937) showed a very low or undetectable level of WT1 mRNA. GATA-1 mRNA was observed in 10 out of the 20 cell lines analyzed, with the expression levels being heterogeneous. GATA-2 mRNA was also observed in 13 out of those 20 cell lines. The correlation index between WT1 and GATA-1 or WT1 and GATA-2 was significant, suggesting a positive relationship between WT1 and GATA-1/-2 mRNA (Figure 1 lower part) . The correlation between GATA-1 and GATA-2 mRNA was also positive. When we examined solid tumor cell lines (SW480, Az521 and TYK-nu-cPr), which express high WT1 mRNA 8 (Figure 1b) , we found that those cell lines with high WT1 mRNA showed high GATA-2, but not GATA-1 mRNA. We also found a high Figure 1 WT1, GATA-1 and GATA-2 mRNA in leukemia cell lines (a) and solid tumor cell lines (b). Relative WT1, GATA-1 and GATA-2 mRNA levels were examined by a quantitative reverse transcriptase-PCR. The internal control was GAPDH. The asterisks denote below the detection limit. The lower panels (c) show the correlation between WT1 and GATA-1, WT1 and GATA-2, and GATA-1 and GATA-2, respectively. 
GATA-
, but its expression levels in the cell line panels were not examined further, as it was reported to express mainly in T lymphocytes and the embryonic brain. 27, 28 We did not analyze PAX family genes because there are clear examples of tumor cell lines in which PAX8 is not expressed but WT1 is, or vice versa. 29, 30 Supplementary Figure 1 illustrates the relative mRNA levels of WT1, GATA-1 and GATA-2 from 23 AML and 3 ALL patient bone marrows. Most leukemia patients (85%) showed WT1 mRNA levels of more than 10 À2 of GAPDH mRNA, whereas the absence of WT1 mRNA (below our detection limit) was observed only in one AML patient. GATA-1 mRNA was very low in one AML case, whereas GATA-2 mRNA was well observed in most. A low correlation index between WT1 mRNA and GATA-1/2 mRNA was obtained (data not shown) probably because of the heterogeneous percentage of blast cells within samples, and because of the remaining erythroid and megakaryocytic lineage cells.
We also examined WT1, GATA-1 and GATA-2 mRNA levels of both normal human hematopoietic stem cell fractions (CD34 þ , CD38 À , Lin À ) and progenitor cell fractions (CD34 þ , CD38
þ , Lin À ) purified from two independent samples according to the method described in the Supplementary information. WT1 mRNA levels of normal stem cell and progenitor cell fractions were significantly lower than those of AML samples with high WT1 mRNA, whereas the GATA-1 and GATA-2 mRNA levels were almost equivalent to those of AML samples. In normal stem cell/progenitor cells, factors other than GATA-1/2 might also be relevant to their WT1 mRNA expression. The contribution of GATA-1/2 to WT1 mRNA expression of normal stem cell/progenitor cell fraction should be further analyzed in future experiments.
As to the WT1 mRNA of the stem cell fraction, Hosen et al. 31 described the very low frequency of normal CD34-positivehematopoietic progenitor cells with WT1 mRNA level similar to those in leukemia cells. Our current study supports their results. Mouthon et al. 32 reported their in situ hybridization, suggesting the gradual increase of GATA-1 mRNA from stem cells to immature erythroblasts and megakaryocytes. In our results, increase of GATA-1 mRNA was observed from stem cell fraction to progenitor cell fraction. Furthermore, Maratheftis et al. 33 reported the upregulation of GATA-1 mRNA of CD34 þ cells in myelodysplastic syndrome compared with that of normal control.
For precise and further analysis of a pure leukemia population, we used leukemia cell lines. Figure 2 illustrates the WT1, GATA-1, GATA-2 and Sp1 protein levels of representative cell lines with either high or low WT1 mRNA. In these cell lines, WT1 protein levels were well correlated with WT1 mRNAs. In WT1-high-leukemia cell lines, GATA-1 and GATA-2 protein levels were higher than those in WT1-low-leukemia cell lines. In the case of SW480, factors other than GATA1 and GATA2 might be involved in its WT1 expression.
5
0 -promoter analysis of WT1 gene
We determined the WT1 transcription start site of K562 cells using the 5 0 rapid amplification of cloned ends method. 26 The start site of K562 cells was 185 bp downstream of the reported site in the National Center for Biotechnology Information database and 380 bp downstream of the one reported earlier. 13, 14 On the basis of our result, we cloned the À1.8-kb region of WT1 5 0 promoter. Figure 3 showed that the most potent promoter activity was located between À224 and À203 bp from exon 1 (Figures 3a and b) . The introduction of a mutation into a putative Sp1 site in this region (Figure 3c ) clearly showed this Sp1 site is essential for the 5 0 -promoter activity of WT1, which is consistent with the result of Cohen et al. 13 It also suggests that this promoter activity was not the sole determinant of the WT1 expression, because K562 and Jurkat cells, which were associated with the high and low WT1 expression, respectively (Figure 2 ), showed similar promoter activity, and the Sp1 protein level did not correlate with the WT1 protein level (Figure 2 ).
Enhancer analysis of WT1 gene
On the basis of results in Figures 2 and 3 as well as earlier reports suggesting the importance of intron 3 and 3 0 enhancers, 15, 20 we prepared luciferase reporter vectors containing À303 bp of the 5 0 -promoter region combined with the intron 3 and/or putative 3 0 enhancer illustrated in Figure 4a . It is clear that the 3 0 enhancer is potent in K562 cells with high WT1 mRNA, but not in Jurkat or HepG2 cells with low WT1 mRNA (Figure 4b) . Interestingly, this 3 0 enhancer was also active in TYK-nu-cPr cells, a solid tumor cell line with high WT1 mRNA. In our analysis, the intron 3 enhancer did not play a major role in WT1 gene expression, as was described earlier, 20 though some additive effect was detected in the presence of 3 0 enhancer. We further analyzed 3 0 enhancer by preparing various truncated forms of this region. Figure 4b showed that the distal region containing three out of six GATA sites was important. In earlier studies, Fraizer et al.
14 reported the importance of 3 0 enhancer, and Wu et al. 15 confirmed their results using EMSA. However, the minimal responsive GATA site within this region has not been determined. Subsequent experiments using a mutated GATA motif introduced into these putative sites (Figure 4c) clearly showed that the minimal region in determining the total promoter/enhancer activity was the most distal GATA site of this enhancer.
The effects of transient expressions of GATA-1 and GATA-2 on WT1 mRNA and WT1 promoter and on WT1 protein of Jurkat and HepG2 cells are illustrated in Figure 5 . GATA-1 overexpression induced WT1 mRNA in both Jurkat cells (1.9 times compared with mock-transfected cells) and HepG2 cells (2.0 times), whereas GATA-2 overexpression increased WT1 mRNA in both Jurkat cells (1.7 times compared with mocktransfected cells) and HepG2 cells (2.4 times), respectively. GATA-induced WT1 protein expression was clearly observed in HepG2 cells (Figure 5b ). The increase of WT1 protein in Jurkat Figure 4 Effects of the intron 3 and 3 0 enhancers of WT1 gene. Effects of the intron 3 and 3 0 enhancers were analyzed by luciferase reporter assay using various combinations of the promoter and enhancers as shown in (a) left. The sequence information was derived from earlier publications 14, 15, 20 and is described in Supplementary information. The mean ±s.d. was calculated from three independent experiments. Data of the relative luciferase activity of control vector (without enhancer elements) of each cell line were regarded as 1.0. In (b and c) deletion and mutation were introduced as illustrated in the left part of each panel. The open circle denotes wild-type GATA site, whereas the solid circle shows mutated GATA site. Data of the relative luciferase activity from luc vector containing only 5 0 promoter and intron 3 enhancer were regarded as 1.0.
GATA-1/2-induced WT1 gene expression through a 3 0 -enhancer GATA site A Furuhata et al cells was only faintly detectable, probably because of the low transfection efficiency (data not shown). However, increased WT1 promoter activity of Jurkat cells by transient GATA-1 and GATA-2 expression was clearly observed (Figure 5a ). siRNA of GATA-1 and GATA-2 effectively inhibits WT1 expression ( Figure 5c ). Our quantitative reverse transcriptase-PCR, western blotting and promoter/enhancer analyses, and siRNA analysis showed that not only GATA-1 but also GATA-2 mRNA was expressed in both leukemia cell lines and clinical samples, and that GATA-1 and GATA-2 are equally effective in WT1 gene expression by binding to a GATA site located in the 3 0 -enhancer region.
EMSA analysis of the distal GATA site of 3 0 enhancer
In EMSA, using the two most distal GATA sites (Figure 6a upper), several retarded bands (a, b, c and d) were observed in K562 nuclear extract, with smaller amounts in Jurkat and Daudi cells (Figure 6a lower) . The intensities of the retarded bands were in proportion to their WT1 mRNA levels ( Figure 2 ). The cold competitor erased all the retarded bands supporting their specificity (Figure 6b left) . The probe with a mutated distal GATA site (mut2), which is the same as m3 in Figure 4c , produced no retarded bands other than band d, suggesting that a, b and c bands are produced by GATA binding to the distal site (Figure 6c left) ; another probe with the mutated proximal GATA site (mut1) (described as m2 in Figure 4c ) produced band patterns similar to those of wild-type probe (wt), supporting the results of our promoter analysis (Figure 4 ). Both anti-GATA-1 and anti-GATA-2 antibody to K562 nuclear extract inhibited bands a, b and c, suggesting that both GATA-1 and GATA-2 were the factors bound to this GATA site (Figure 6d upper) . We also examined solid tumors, TYK-nu-cPr and several other cell lines. EMSA of TYK-nu-cPr differed from those of k562 cells (Figure 6a lower-right) . In addition to the commonly observed band d, we also observed bands e and f. They are also competed with the cold competitor (Figure 6b right) . Interestingly, the band pattern of HL60 with GATA-2, but not GATA-1 expression, was similar to that of TYK-n-cPr (Figure 6a ). The probe with the mutated GATA site (mut1), but not mut2, produced band e, which was reduced by anti-GATA-2 but not anti-GATA-1 antibody (Figures 6c and d) .
The molecular weight and function of GATA-1 and GATA-2 were not markedly different. The difference observed in the EMSA pattern between K562 and TYK-nu-cPr was unexpected and quite interesting. Treatment with anti-GATA-1 and anti-GATA-2 antibodies showed that both GATA-1 and GATA-2 bound to the same GATA motif, and that GATA-2, but not GATA-1, was bound in TYK-nu-cPr cells. The complex formation between the GATA family and other cofactors might explain the different patterns observed. Further analysis is needed to elucidate the real binding mode of these GATA factors.
Chromatin immunoprecipitation assay using anti-GATA-1 and anti-GATA-2 antibodies To confirm our EMSA data, a chromatin immunoprecipitation assay was carried out. Figure 7 shows that both GATA-1 and GATA-2 bound the 3 0 enhancer sequence in K562 cells, and that GATA-2, but not GATA-1, bound this enhancer in TYK-nu-cPr cells, a finding consistent with our promoter/enhancer analysis and EMSA data.
Conclusion
Taken together, these results showed that not only GATA-1 14, 15 but also GATA-2 bound to the most distal GATA site of Figure 5 Effect of modulation of GATA family genes. GATA-1 and GATA-2 expression vectors were transiently introduced to Jurkat and HepG2 cells whose original WT1 mRNA levels were low. Under overexpression conditions shown in the upper parts of a and b, we determined WT1 promoter/enhancer activities using the e2 reporter of Figure 4c (a) , or WT1 protein levels (b). Promoter/enhancer activity was expressed with the mock transfectant regarded as 1.0. (c) siRNAs of GATA-1 and GATA-2 were transfected as described in the Materials and methods. At 48 h after transfection, the WT1 protein level was evaluated by western blotting with b-actin as the internal control ( right). Scramble siRNA was used as the control of the specificity of siRNAs used.
GATA-1/2-induced WT1 gene expression through a 3 0 -enhancer GATA site A Furuhata et al 3 0 enhancer, which was the important determinant of the WT1 mRNA level in some cell lines. Furthermore, this 3 0 enhancer is not unique to a hematopoietic lineage but has also proven effective in solid tumor cell lines. The regulatory mechanism of WT1 gene expression described in these experiments provides the fundamental information on the WT1 biology of malignant diseases. Figure 6 (a) EMSA analysis using probes covering the two distal GATA sites. Using biotin-labeled probes containing the two most distal GATA sites (oligo wild type, GATA mut1 and GATA mut2), the binding of transcription factor was examined using nuclear extracts from K562, Jurkat, Daudi, or HL60 cells (left) and TYk-nu-cPr, SW480, Az521 or HepG2 cells (right). Retarded bands were named a, b, c, d, e and f, respectively. (b) In addition to the labeled probe, a cold probe (x1-x10 excess) was added to the reaction mixture of K562 and TYK-nu-cPr cells, and EMSA was carried out. (c) A labeled probe with wild-type or with the mutated GATA site (GATA mut1 or GATA mut2 shown in (a) was used. (d) Anti-GATA-1 (final concentration: from 0.1 to 10 mg/ml) or anti-GATA-2 (final concentration: from 0.1 to 10 mg/ml) was added to nuclear extracts before incubation with the labeled DNA probe, as described in Materials and methods. Figure 7 Chromatin immunoprecipitation assay was carried out as described in Materials and methods. After immunoprecipitation with anti-GATA-1 or anti-GATA-2 antibody, DNA was purified. PCR was performed using a primer set covering the region 123 bp long containing the two most distal GATA sites (Materials and methods). For specificity control, samples treated with unrelated IgG or PBS (no Ab) are also shown.
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